EPCAM and oropharyngeal carcinoma: In order to exclude a confounding impact of sublocalizations of tumors on the clinical outcome of the four EGFR/EpCAM patient subgroups, we analyzed the most prominent entity, i.e., oropharyngeal carcinomas (n = 105).